AbbVie Inc (ABBV)vsElectrocore LLC (ECOR)
ABBV
AbbVie Inc
$286.40
-0.14%
HEALTHCARE · Cap: $504.37B
ECOR
Electrocore LLC
$8.42
+8.51%
HEALTHCARE · Cap: $67.53M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 174076% more annual revenue ($64.39B vs $36.97M). ABBV leads profitability with a 9.8% profit margin vs -40.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
ECOR
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$286.40
$133.43 premium
Margin of Safety
+82.5%
Fair Value
$31.24
Current Price
$8.42
$22.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Revenue surging 28.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -478.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : ECOR
The strongest argument for ECOR centers on Debt/Equity, Revenue Growth. Revenue growth of 28.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : ECOR
The primary concerns for ECOR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while ECOR is a growth play — different risk/reward profiles.
ECOR carries more volatility with a beta of 1.05 — expect wider price swings.
ECOR is growing revenue faster at 28.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 26/100) and 10.2% revenue growth. ECOR offers better value entry with a 82.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Electrocore LLC
HEALTHCARE · MEDICAL DEVICES · USA
electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?